The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes

Diabetologia

Volumn 60, Issue 7, 2017, Pages 1185-1189

  Bloem, Stef J ^a   Roep, Bart O ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

B lymphocytes; Germinal centre; Immunopathogenesis; Islet autoantibodies; Lymphoid follicles; Pancreas draining lymph nodes

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; IMMUNOGLOBULIN; RITUXIMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DIABETIC PATIENT; EDITORIAL; FOLLICULAR DENDRITIC CELL; GERMINAL CENTER; GLYCEMIC CONTROL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREATIC LYMPH NODE; PRIORITY JOURNAL; REGULATORY B LYMPHOCYTE; ANIMAL;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS;

EID: 85018819786     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4284-5     Document Type: Editorial

References (37)

1. Wong FS, Hu C, Xiang Y, Wen L (2010) To B or not to B—pathogenic and regulatory B cells in autoimmune diabetes. Curr Opin Immunol 22:723–731
2. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581
3. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM (1998) B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161:3912–3918
4. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A (1997) B cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46:941–946
5. Holz A, Dyrberg T, Hagopian W, Homann D, von Herrath M, Oldstone MB (2000) Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes. J Immunol 165:5945–5953
6. Roep BO, Atkinson M (2004) Animal models have little to teach us about type 1 diabetes: 1. In support of this proposal. Diabetologia 47:1650–1656
7. Roep BO, Atkinson M, von Herrath M (2004) Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol 4:989–997
8. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–2738
9. Greeley SA, Katsumata M, Yu L et al (2002) Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 8:399–402
10. Koczwara K, Bonifacio E, Ziegler AG (2004) Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes 53:1–4
11. Martin S, Wolf-Eichbaum D, Duinkerken G et al (2001) Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 345:1036–1040
12. Willcox A, Richardson SJ, Walker LS, Kent SC, Morgan NG, Gillespie KM (2017) Germinal centre frequency is decreased in pancreatic lymph nodes from individuals with recent-onset type 1 diabetes. Diabetologia. doi:10.1007/s00125-017-4221-7
13. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG (2009) Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 155:173–181
14. van Lummel M, van Veelen PA, de Ru AH et al (2016) Dendritic cells guide islet autoimmunity through a restricted and uniquely processed peptidome presented by high-risk HLA-DR. J Immunol 196:3253–3263
15. Peakman M, Stevens EJ, Lohmann T et al (1999) Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 104:1449–1457
16. Arif S, Tree TI, Astill TP et al (2004) Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 113:451–463
17. Demeester S, Keymeulen B, Kaufman L et al (2015) Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual beta-cell function in recent-onset type 1 diabetes. Diabetes Care 38:644–651
18. Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479
19. Bingley PJ, Bonifacio E, Gale EA (1993) Can we really predict IDDM? Diabetes 42:213–220
20. Roep BO, Peakman M (2012) Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2:a007781
21. Roep BO, Duinkerken G, Schreuder GM, Kolb H, de Vries RR, Martin S (1996) HLA-associated inverse correlation between T cell and antibody responsiveness to islet autoantigen in recent-onset insulin-dependent diabetes mellitus. Eur J Immunol 26:1285–1289
22. Harrison LC, Honeyman MC, DeAizpurua HJ et al (1993) Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. Lancet 341:1365–1369
23. Coppieters KT, Dotta F, Amirian N et al (2012) Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 209:51–60
24. Roep BO (2013) Beta-cells, autoimmunity, and the innate immune system: “un menage a trois”? Diabetes 62:1821–1822
25. Zaldumbide A, Alkemade G, Carlotti F et al (2013) Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo. Mol Ther 21:1592–1601
26. Skowera A, Ellis RJ, Varela-Calvino R et al (2008) CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 118:3390–3402
27. Lampeter EF, Homberg M, Quabeck K et al (1993) Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 341:1243–1244
28. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608
29. Weenink SM, Lo J, Stephenson CR et al (2009) Autoantibodies and associated T cell responses to determinants within the 831-860 region of the autoantigen IA-2 in type 1 diabetes. J Autoimmun 33:147–154
30. Oak S, Gilliam LK, Landin-Olsson M et al (2008) The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A 105:5471–5476
31. Colagiuri S, Leong GM, Thayer Z et al (1996) Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol 14(Suppl 15):S93–S97
32. Orban T, Kis JT (2011) Prevention of type 1 diabetes mellitus using a novel vaccine. Ther Adv Endocrinol Metab 2:9–16
33. Tooley JE, Herold KC (2014) Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes 21:287–292
34. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152
35. Pescovitz MD, Greenbaum CJ, Bundy B et al (2014) B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 37:453–459
36. Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30:221–241
37. Herold KC, Pescovitz MD, McGee P et al (2011) Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 187:1998–2005